Go Pro
NASDAQ:QNTM

Quantum Biopharma Q2 2026 Earnings Report

Quantum Biopharma logo
$3.24 +0.29 (+9.83%)
As of 09/4/2026 04:00 PM Eastern

Quantum Biopharma EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.41
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Quantum Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quantum Biopharma Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Quantum Biopharma's next earnings date is estimated for Friday, November 6, 2026, based on past reporting schedules.

Conference Call Resources

Quantum Biopharma Earnings Headlines

Rodman & Renshaw Initiates Coverage on Quantum Biopharma (NASDAQ:QNTM)
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
Quantum Biopharma Provides Corporate Update
See More Quantum Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email.

About Quantum Biopharma

Quantum Biopharma (NASDAQ:QNTM) is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

View Quantum Biopharma Profile